Download Frelin-Short Biography-A3ES

Short biography
Lars Frelin
Karolinska Institutet
Short biography
Name:
Dr. Lars Frelin, Associate Professor in Virology.
Birth data:
March 25, 1977.
Working address: Karolinska Institutet
Department of Laboratory Medicine
Division of Clinical Microbiology, F68
Karolinska University Hospital Huddinge
S-141 86 Stockholm, Sweden
P: +46-8-52483632, +46-70-4243001
F: +46-8-58587933
[email protected]
www.ki.se
Current scientific activities:
Associate Professor at Karolinska Institutet, Department of Laboratory Medicine,
Division of Clinical Microbiology, Karolinska University Hospital Huddinge.
Principal investigator (PI) and group leader in the “Viral Hepatitis Research
Group”. Main research focus is establishment and evaluation of in vivo and in
vitro models of hepatitis B and C virus infection and vaccine development. Dr.
Frelin has several national and international research collaborators with joint
research projects. He has research funding from national and international
foundations, government funds, and funds from pharmaceutical companies. Dr.
Frelin is the Chairman of the International Committee for the Study Programme in
Biomedical Laboratory Science and lecturer at Karolinska Institutet. Dr. Frelin is a
frequent referee for several scientific journals. He has served as an evaluator for
research grants and research positions at Karolinska Institutet. He is also a
frequent member of thesis evaluation committees at Karolinska Institutet.
Current and previous positions:
2013 – present
Associate Professor in Virology, Karolinska Institutet.
2013 – present
Chairman of the International Committee for the Study
Programme in Biomedical Laboratory Science at Karolinska
Institutet.
2013 – present
Academic coordinator for a Linnaeus-Palme cooperation
(student- and staff exchange) between Karolinska Institutet
and Burapha University, Faculty of Allied Health Science,
Chonburi, Thailand.
1
Short biography
Lars Frelin
Karolinska Institutet
2013 – present
Member of the management team at Division of Clinical
Microbiology, Karolinska Institutet.
2012 – present
Consultant at ChronTech Pharma AB.
2011 – present
Member of the Research Council at Department of
Laboratory Medicine, Karolinska Institutet.
2010 – 2013
Senior Researcher, Karolinska Institutet.
2007 – 2009
Postdoctoral fellow, Karolinska Institutet.
2005 – 2006
Postdoctoral fellow, Vaccine Research Institute of San
Diego, CA, USA and Scripps Research Institute, La Jolla,
CA, USA.
2001 – 2004
PhD in Virology, Karolinska Institutet.
1997 – 2000
BSc in Molecular Biology, Södertörn University.
Selected academic distinctions and other merits:
*Riksföreningen hepatit C honorary award for the initiative for the research
project: “Vertical and Horizontal Health Communication: Case Hepatitis C”, 2013.
*Jonas Söderqvists award for basic research in virology and immunology, 2007.
*Co-developed and tested the world’s first DNA vaccine delivered intramuscularly
in combination with in vivo electroporation for treatment of chronic hepatitis C
virus infected patients at Karolinska University Hospital Huddinge, 2007-2010.
Selected Publications:
Ahlén G, Holmström F, Petrova A, Alheim M, and Frelin L. Long-term functional
duration of immune responses to HCV NS3/4A induced by DNA vaccination.
Gene Therapy (2014);doi:10.1038/gt.2014.48. PMID: 24871581
Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I,
Sardesai NY, Vahlne A, Frelin L, and Sällberg M. Therapeutic DNA vaccination
using in vivo electroporation followed by standard of care therapy in patients with
genotype 1 chronic hepatitis C. Molecular Therapy (2013);21(9):1796-805. PMID:
23752314
Fournillier A#, Frelin L#§, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström
F, Broderick K, Sardesai N, Bonnefoy J-Y, Inchauspe G, and Sällberg M. A
2
Short biography
Lars Frelin
Karolinska Institutet
heterologous prime/boost vaccination-strategy enhances the immunogenicity of
therapeutic vaccines for hepatitis C virus. Journal of Infectious Diseases
(2013);208(6):1008-1019. PMID: 23776192
# =AF and LF contributed equally to this work.
§ =corresponding author (LF).
Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, and Brenndörfer ED.
Non-structural 3 protein expression is associated with T cell protein tyrosine
phosphatase and viral RNA levels in chronic hepatitis C patients. Biochemical
and Biophysical Research Communications (2013); 433(1):31-5. PMID:
23454379
Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, Broderick KE, Chen
M, Ahlén G, and Frelin L. A synthetic codon-optimized hepatitis C virus
nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in
wild-type and NS5A-transgenic mice. Journal of Immunology (2013);190(3):111324. PMID: 23284053
Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED,
Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, and Chen M. TCRredirected human T cells inhibit hepatitis C virus replication: Hepatotoxic potential
is linked to antigen specificity and functional avidity. Journal of Immunology
(2012);189(9):4510-9. PMID: 23024278
Ahlén G, Chen A, Roe B, Falkeborn T, Frelin L, Hall WW, Sällberg M, and
Söderholm J. Limited effect on viral fitness of mutations within the
immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3
non-structural 3/4A protease. Journal of General Virology (2012);93(Pt 8):1680-6.
PMID: 22592266
Pasetto A, Frelin L, Yasmeen A, Lohmann V, Bartenschlager R, Koh S,
Magalhaes I, Maeurer M, Sällberg M, and Chen M. Generation of T cell receptors
targeting a genetically stable and immunodominant cytotoxic T lymphocyte
epitope within the hepatitis C virus non-structural 3 protein. Journal of General
Virology (2012):93(Pt 2):247-58. PMID: 22071510
Lee BO, Jones JE, Peters CJ, Whitacre D, Frelin L, Hughes J, Kim W-J, and
Milich DR. Identification of a unique double negative (DN) Treg cell population.
Immunology (2011):134(4):434-47. PMID: 22044159
Malik-Riaz I, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, and
Frelin L. A bi-functional hepatitis B virus core antigen chimera activates HBcAgspecific T cells and preS1-specific antibodies. Scandinavian Journal of Infectious
Diseases (2012):44(1):55-9. PMID: 21933033
3